Compare Stocks: SYRE, ALNY, ROIV, and UTHR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$234.03 +4.3%	$239.10	$197.81 ▼ $495.55	$30.04B	0.28	1.29 million shs	1.26 million shs
ROIV Roivant Sciences	$34.04 +1.2%	$36.66	$16.88 ▼ $42.50	$24.28B	1.1	7.27 million shs	4.57 million shs
SYRE Spyre Therapeutics	$80.10 +1.9%	$92.49	$21.15 ▼ $110.18	$8.01B	3.1	1.64 million shs	1.15 million shs
UTHR United Therapeutics	$541.51 +0.3%	$513.58	$409.07 ▼ $609.35	$23.16B	0.49	1.04 million shs	532,388 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+0.29%	+0.03%	-10.21%	-20.72%	-52.18%
ROIV Roivant Sciences	+0.81%	-3.25%	-18.04%	-0.91%	+105.00%
SYRE Spyre Therapeutics	-2.26%	-2.75%	-13.40%	-16.46%	+274.43%
UTHR United Therapeutics	-0.62%	-0.91%	+7.43%	+2.08%	+24.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$234.03 +4.3%	$239.10	$197.81 ▼ $495.55	$30.04B	0.28	1.29 million shs	1.26 million shs
ROIV Roivant Sciences	$34.04 +1.2%	$36.66	$16.88 ▼ $42.50	$24.28B	1.1	7.27 million shs	4.57 million shs
SYRE Spyre Therapeutics	$80.10 +1.9%	$92.49	$21.15 ▼ $110.18	$8.01B	3.1	1.64 million shs	1.15 million shs
UTHR United Therapeutics	$541.51 +0.3%	$513.58	$409.07 ▼ $609.35	$23.16B	0.49	1.04 million shs	532,388 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+0.29%	+0.03%	-10.21%	-20.72%	-52.18%
ROIV Roivant Sciences	+0.81%	-3.25%	-18.04%	-0.91%	+105.00%
SYRE Spyre Therapeutics	-2.26%	-2.75%	-13.40%	-16.46%	+274.43%
UTHR United Therapeutics	-0.62%	-0.91%	+7.43%	+2.08%	+24.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.88	Moderate Buy	$364.95	55.94% Upside
ROIV Roivant Sciences	2.79	Moderate Buy	$45.64	34.07% Upside
SYRE Spyre Therapeutics	2.94	Moderate Buy	$110.40	37.83% Upside
UTHR United Therapeutics	2.71	Moderate Buy	$642.69	18.69% Upside

Current Analyst Ratings Breakdown

Latest SYRE, ALNY, ROIV, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	UTHR United Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell	$368.00
10/15/2026	ALNY Alnylam Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$550.00 ➝ $354.00
10/14/2026	UTHR United Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$728.00
10/14/2026	ALNY Alnylam Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$340.00 ➝ $320.00
10/14/2026	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Equal Weight	$256.00 ➝ $253.00
10/12/2026	ROIV Roivant Sciences	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/12/2026	ROIV Roivant Sciences	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Peer Perform
10/11/2026	SYRE Spyre Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$120.00
10/11/2026	SYRE Spyre Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/8/2026	UTHR United Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$677.00 ➝ $708.00
10/8/2026	ALNY Alnylam Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$350.00 ➝ $345.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	8.43	$2.92 per share	80.28	$5.97 per share	39.20
ROIV Roivant Sciences	$8.26M	2,976.73	N/A	N/A	$7.35 per share	4.63
SYRE Spyre Therapeutics	$890K	9,171.90	N/A	N/A	$7.21 per share	11.11
UTHR United Therapeutics	$3.18B	7.30	$33.08 per share	16.37	$164.81 per share	3.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	43.50	24.10	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	19.32	17.86	3.86	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest SYRE, ALNY, ROIV, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q2 2027	ROIV Roivant Sciences	-$0.41	N/A	N/A	N/A	$3.74 million	N/A
11/4/2026	Q3 2026	UTHR United Therapeutics	$6.21	N/A	N/A	N/A	$784.57 million	N/A
11/3/2026	Q3 2026	SYRE Spyre Therapeutics	-$0.7764	N/A	N/A	N/A	N/A	N/A
10/29/2026	Q3 2026	ALNY Alnylam Pharmaceuticals	$1.75	N/A	N/A	N/A	$1.43 billion	N/A
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
ROIV Roivant Sciences	N/A	16.72	16.72
SYRE Spyre Therapeutics	N/A	18.53	18.53
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
ROIV Roivant Sciences	64.76%
SYRE Spyre Therapeutics	80.39%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
ROIV Roivant Sciences	8.80%
SYRE Spyre Therapeutics	15.69%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable
SYRE Spyre Therapeutics	112	101.91 million	85.92 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

SYRE, ALNY, ROIV, and UTHR Headlines

Recent News About These Companies

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

3 hours ago | marketbeat.com

United Therapeutics (UTHR) Settles Litigation And Resets Pulmonary Hypertension Competition

October 15 at 11:51 AM | finance.yahoo.com

Is United Therapeutics (UTHR) Undervalued After Its Legal Settlement?

October 15 at 6:51 AM | uk.finance.yahoo.com

United Therapeutics (UTHR) Stock May Be Undervalued Following The Litigation Settlement

October 15 at 6:51 AM | finance.yahoo.com

What to Know as Liquidia, United Therapeutics Settlement Sends LQDA Stock Soaring

October 14 at 4:51 PM | barchart.com

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

October 14 at 2:41 PM | zacks.com

Liquidia shares surge 25% as settlement ends United Therapeutics litigation

October 14 at 1:16 PM | proactiveinvestors.com

SGIOY or UTHR: Which Is the Better Value Stock Right Now?

October 14 at 12:40 PM | zacks.com

United Therapeutics Corp. (UTHR) PT Raised to $728 at Jefferies

October 14 at 12:40 PM | streetinsider.com

LQDA stock rockets 40% today – BTIG calls United Therapeutics settlement better than best-case scenario

October 14 at 12:40 PM | msn.com

Liquidia adds over 30% on United Thera. settlement; BTIG upgrades

October 14 at 12:40 PM | seekingalpha.com

SGIOY or UTHR: Which Is the Better Value Stock Right Now?

October 14 at 12:40 PM | finance.yahoo.com

United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%

October 14 at 11:30 AM | 247wallst.com

United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%

October 14 at 11:05 AM | 247wallst.com

Liquidia shares jump as United Therapeutics settlement clears major YUTREPIA overhang

October 14 at 10:51 AM | quiverquant.comQ

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

October 14 at 9:56 AM | zacks.com

This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.

October 14 at 8:57 AM | barrons.com

Liquidia Settles Bitter Fight With United Therapeutics

October 14 at 8:30 AM | benzinga.com

United Therapeutics Reaches Major Pulmonary Hypertension Settlement

October 14 at 7:51 AM | tipranks.com

Liquidia Reaches Global Patent Settlement, Refines Financing

October 14 at 6:30 AM | tipranks.com

Liquidia Stock (LQDA) Pops as $380.7M Deal Ends Legal Battle with United Therapeutics

October 14 at 5:11 AM | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE, ALNY, ROIV, and UTHR Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$234.03 +9.56 (+4.26%)

Closing price 04:00 PM Eastern

Extended Trading

$233.23 -0.80 (-0.34%)

As of 07:30 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$34.04 +0.42 (+1.25%)

Closing price 04:00 PM Eastern

Extended Trading

$34.04 +0.01 (+0.01%)

As of 07:30 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Spyre Therapeutics NASDAQ:SYRE

$80.10 +1.47 (+1.87%)

Closing price 04:00 PM Eastern

Extended Trading

$80.12 +0.03 (+0.03%)

As of 07:30 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

United Therapeutics NASDAQ:UTHR

$541.51 +1.48 (+0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$541.55 +0.04 (+0.01%)

As of 07:30 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SYRE, ALNY, ROIV, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SYRE, ALNY, ROIV, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SYRE, ALNY, ROIV, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE, ALNY, ROIV, and UTHR Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Roivant Sciences NASDAQ:ROIV

Spyre Therapeutics NASDAQ:SYRE

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SYRE, ALNY, ROIV, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SYRE, ALNY, ROIV, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SYRE, ALNY, ROIV, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE, ALNY, ROIV, and UTHR Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Roivant Sciences NASDAQ:ROIV

Spyre Therapeutics NASDAQ:SYRE

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools